Literature DB >> 21901817

CD38 through the life of a murine B lymphocyte.

Felipe Vences-Catalán1, Leopoldo Santos-Argumedo.   

Abstract

CD38 is a 45 kDa transmembrane receptor expressed in B lymphocytes and other cells from the immune system. It is involved in apoptosis, cell activation, differentiation, and proliferation. CD38 has been used extensively to classify various subpopulations of lymphocytes in both humans and mice. It has also been used as a marker of poor prognosis in some lymphoid pathologies. However, CD38 is not a marker but rather an ectoenzyme and a receptor, where it performs several functions. The CD38 signaling pathway has only been partially studied in various cells of the immune system, where apparently the signaling is different depending on the lineage and differentiation state of the cell, leading to distinct outcomes. In this review, we provide an overview of well-established roles of CD38 signaling B lymphocytes from mice. We also discuss areas that need further clarification to get a broader image of how CD38 performs different functions in B cells and to understand its role in B lymphocyte biology under normal versus pathological conditions.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21901817     DOI: 10.1002/iub.549

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  17 in total

1.  CD38 expression in early B-cell precursors contributes to extracellular signal-regulated kinase-mediated apoptosis.

Authors:  Héctor Romero-Ramírez; Monserrat Teresa Morales-Guadarrama; Rosana Pelayo; Rubén López-Santiago; Leopoldo Santos-Argumedo
Journal:  Immunology       Date:  2015-02       Impact factor: 7.397

2.  Monitoring of Measurable Residual Disease in Multiple Myeloma by Multiparametric Flow Cytometry.

Authors:  Kah Teong Soh; Paul K Wallace
Journal:  Curr Protoc Cytom       Date:  2019-07-17

3.  CD38-mediated Inhibition of Bruton's Tyrosine Kinase in Macrophages Prevents Endotoxemic Lung Injury.

Authors:  Joseph Farahany; Yoshikazu Tsukasaki; Amitabha Mukhopadhyay; Manish Mittal; Saroj Nepal; Chinnaswamy Tiruppathi; Asrar B Malik
Journal:  Am J Respir Cell Mol Biol       Date:  2022-02       Impact factor: 6.914

4.  Interferon gamma modulation of disease manifestation and the local antibody response to alphavirus encephalomyelitis.

Authors:  Victoria K Baxter; Diane E Griffin
Journal:  J Gen Virol       Date:  2016-09-22       Impact factor: 3.891

5.  All-trans-retinoic acid and CD38 ligation differentially regulate CD1d expression and α-galactosylceramide-induced immune responses.

Authors:  Qiuyan Chen; A Catharine Ross
Journal:  Immunobiology       Date:  2014-09-16       Impact factor: 3.144

6.  The CD19/CD81 complex physically interacts with CD38 but is not required to induce proliferation in mouse B lymphocytes.

Authors:  Felipe Vences-Catalán; Ranjani Rajapaksa; Shoshana Levy; Leopoldo Santos-Argumedo
Journal:  Immunology       Date:  2012-09       Impact factor: 7.397

7.  An optimized method for enumerating CNS derived memory B cells during viral-induced inflammation.

Authors:  Krista D DiSano; Stephen A Stohlman; Cornelia C Bergmann
Journal:  J Neurosci Methods       Date:  2017-05-08       Impact factor: 2.390

8.  Gene expression profiling in peripheral blood mononuclear cells of patients with common variable immunodeficiency: modulation of adaptive immune response following intravenous immunoglobulin therapy.

Authors:  Marzia Dolcino; Giuseppe Patuzzo; Alessandro Barbieri; Elisa Tinazzi; Monica Rizzi; Ruggero Beri; Giuseppe Argentino; Andrea Ottria; Claudio Lunardi; Antonio Puccetti
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

9.  Successful TB treatment induces B-cells expressing FASL and IL5RA mRNA.

Authors:  Ilana C van Rensburg; Chandre Wagman; Kim Stanley; Caroline Beltran; Katharina Ronacher; Gerhard Walzl; Andre G Loxton
Journal:  Oncotarget       Date:  2017-01-10

Review 10.  The expansion of targetable biomarkers for CAR T cell therapy.

Authors:  Michelle H Townsend; Gajendra Shrestha; Richard A Robison; Kim L O'Neill
Journal:  J Exp Clin Cancer Res       Date:  2018-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.